Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | RARB | P10826 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6709192 | 0.91 | GRIK1 (0.42) | GRIK1ROCK1SERPINE1RXFP1 | |
| SCHEMBL6712244 | 0.91 | GRIK1 (0.38) | GRIK1ROCK1RARBNR1H4RXFP1 | |
| SCHEMBL6712092 | 0.89 | RARB (0.42) | ROCK1RARBNR1H4TP53 | |
| SCHEMBL6712077 | 0.88 | GRIK1 (0.39) | GRIK1ROCK1F11KLKB1RXFP1 | |
| SCHEMBL6710342 | 0.85 | GRIK1 (0.42) | GRIK1ROCK1F11KLKB1CNR1 | |
| SCHEMBL6713737 | 0.85 | GRIK1 (0.44) | GRIK1ROCK1F11KLKB1RXFP1 | |
| SCHEMBL6711901 | 0.85 | GRIK1 (0.41) | GRIK1ROCK1F11KLKB1RXFP1 | |
| SCHEMBL6713384 | 0.84 | GRIK1 (0.47) | GRIK1ROCK1F11KLKB1RXFP1 | |
| SCHEMBL6709222 | 0.84 | GRIK1 (0.40) | GRIK1ROCK1RXFP1SMN1; SMN2 | |
| SCHEMBL6711650 | 0.84 | SERPINE1 (0.38) | ROCK1SERPINE1CNR1PPARGNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | GRIK1 3885/4885ROCK1 4830/4885RARB 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.